(Reuters) - BOSTON, April 25 - Biotechnology company Genzyme Corp. reported higher-than-expected quarterly earnings on Wednesday and raised its full year forecast, driven by strong sales of its drugs for rare and chronic diseases.
The Cambridge, Massachusetts-based company said net income rose to $158.2 million, or 57 cents a share, in the first quarter from $101 million, or 37 cents a share, a year ago. Revenue rose to $883.2 million from $730.8 million a year ago.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment